Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment (RITMUS-AF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04174859
Recruitment Status : Recruiting
First Posted : November 22, 2019
Last Update Posted : March 13, 2020
Sponsor:
Collaborator:
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Bayer

Brief Summary:

While it is well known that stopping or changing medication with blood thinners in patients who suffer from non-valvular atrial fibrillation (NVAF) increases the risk of ischemic stroke (a condition which occurs when a vessel supplying blood to the brain is obstructed), bleeding or thromboembolism (a condition that happens when a blood clot forms elsewhere in the body and travels through the blood stream to plug another vessel), limited data are available on the number of NVAF patients and the reasons why NVAF patients in Italy stop or change their treatment with blood thinners to prevent stroke or thromboembolism.

By following the NVAF patients in routine clinical practice in Italy who are treated with rivaroxaban to prevent stroke or systemic embolism researchers want to find out how many NVAF patients and for what reasons NVAF patients stopped or changed rivaroxaban treatment. Study data will be collected through patients' routine visits at their treating doctor over a period of 24 months for each patient.


Condition or disease Intervention/treatment
Non-valvular Atrial Fibrillation Drug: Rivaroxaban (Xarelto, BAY59-7939)

Layout table for study information
Study Type : Observational
Estimated Enrollment : 800 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Rivaroxaban Treatment Discontinuation Rates in Routine Clinical Practice in Italy in Patients With Non-valvular Atrial Fibrillation
Actual Study Start Date : December 10, 2019
Estimated Primary Completion Date : June 1, 2023
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Rivaroxaban

Group/Cohort Intervention/treatment
NVAF patients
Start treatment with rivaroxaban at the discretion of physician.
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Treatment dose is following the description of physicians.




Primary Outcome Measures :
  1. Date of start of rivaroxaban treatment [ Time Frame: 24 months ]
  2. Date of stop of rivaroxaban treatment [ Time Frame: 24 months ]
  3. Number of patients who discontinue (i.e: number of discontinuation) from study initiation to end of observation/follow up. [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Reasons for discontinuation of rivaroxaban therapy [ Time Frame: 24 months ]
    • therapy discontinuation due to adverse event (AE)
    • therapy discontinuation for non AE related reason
    • physician decision
    • patient lost to follow up, no remote contact
    • patient decision (not related to AE)
    • patient is in stable sinus rhythm
    • patient decided to terminate study participation but agreed to further use of data collected so far.
    • patient decided to terminate study participation and refused further use of collected data.
    • Patient died
    • Treatment switch

  2. Reason for dose change of rivaroxaban therapy [ Time Frame: 24 months ]
    • Change in Creatinine Clearance (CrCL)
    • Insufficient therapeutic effect
    • Adverse event

  3. Reason for switch to other therapy [ Time Frame: 24 months ]
    • Ischemic event
    • Bleeding and site of bleeding
    • Adverse drug reaction
    • Drug interaction with other therapies
    • New treatment after switch

  4. Treatment adherence: Self-reported medication adherence measured by the MMAS-8 (Morinsky Scale score) [ Time Frame: 24 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
NVAF patients who are treated with rivaroxaban to prevent stroke or non-CNS systemic embolism. Owing to the observational study design, patients will only be enrolled in the study if the decision to treat with rivaroxaban has been made by the treating physician in advance and independent of study inclusion. The decision to prescribe rivaroxaban is solely at the discretion of the investigator and made in accordance with his/her experience in accordance to SmPC.
Criteria

Inclusion Criteria:

  • Age >= 18
  • Patient with a diagnosis of NVAF
  • New user to rivaroxaban, naïve or non naïve to treatment with oral anticoagulant
  • Patient for whom the decision to initiate treatment with rivaroxaban was made as per physician's routine treatment practice for prevention of stroke and non-central nervous system (CNS) systemic embolism.
  • Signed an informed consent

Exclusion Criteria:

  • Patient with heart valve replacement
  • Patient is participating in an investigational program with interventions outside of routine clinical practice

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04174859


Contacts
Layout table for location contacts
Contact: Bayer Clinical Trials Contact (+)1-888-84 22937 clinical-trials-contact@bayer.com

Locations
Layout table for location information
Italy
Many locations Recruiting
Multiple Locations, Italy
Sponsors and Collaborators
Bayer
Janssen Research & Development, LLC

Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT04174859    
Other Study ID Numbers: 20999
First Posted: November 22, 2019    Key Record Dates
Last Update Posted: March 13, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Bayer:
Atrial Fibrillation (AF)
NVAF
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Rivaroxaban
Factor Xa Inhibitors
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants